ATM Inhibitor SYH2051 clinical trials
Also written SYH2051.
How each study uses ATM Inhibitor SYH2051 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ATM Inhibitor SYH2051 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2023 (1)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2) · Fujian Cancer Hospital (1) · CSPC Megalith Biopharmaceutical Co.,Ltd. (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test ATM Inhibitor SYH2051.
- Jun 2027Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid TumorsPhase 1/2 · CSPC Megalith Biopharmaceutical Co.,Ltd.
Studies
Open first, then newest update. How each study uses ATM Inhibitor SYH2051 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid TumorsNot yet recruitingPhase 1/2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07911579Written as SYH2051
- Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid TumorsNot yet recruitingPhase 1/2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT06775236Written as SYH2051 tablets
- A Study of SYH2051 Monotherapy in Advanced Solid Tumors or in Combination With Radiotherapy in Locally Advanced Head and Neck CancerRecruitingPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06011291Written as SYH2051 tablets
- A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal TumorsActive, not recruitingNot applicableFujian Cancer HospitalNCT07104877Written as SYH2051
What changed recently
From the registry's own updates since Oct 14, 2026.